Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Next Previous
Trial Profile

A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gebasaxturev (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms CALM
  • Sponsors Viralytics

    • Most Recent Events

    • 31 Aug 2021 Results published in the Journal of Clinical Oncology
    • 07 Jun 2016 Combined results of parent and extension study assessing the dynamics of tumor response (n=70) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 20 Apr 2016 Results (extension study) assessing the impact of CVA21 on immune cell infiltrates and immune checkpoint molecules within treated lesions presented at the 107th Annual Meeting of the American Association for Cancer Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top